Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1629 4100
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18550642 | METHOD OF DECREASING THE POPULATION OF FUSOBACTERIA IN THE GUT MICROBIOME | Non-Final OA | DSM IP Assets B.V. |
| 18706266 | CANNABIGEROL FOR TREATMENT OF SEIZURES AND EPILEPSY | Non-Final OA | The Regents of the University of California |
| 18266525 | SMALL MOLECULES AND THEIR USE AS MALT1 INHIBITORS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18635508 | TREATMENT OF CANCERS OR NEOPLASMS BY INHIBITING KIF15 | Non-Final OA | University of Kansas |
| 18728925 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18640931 | N-SUBSTITUTED C6 CYCLYL CARBOXAMIDE COMPOUNDS AND USES THEREOF | Non-Final OA | ALCON INC. |
| 18728431 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18542376 | COMPOUNDS THAT SYNERGIZE WITH COPPER TO KILL STREPTOCOCCUS PNEUMONIAE | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18035313 | SULFUROUS COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | Non-Final OA | Merck Patent GmbH |
| 18768902 | PHARMACEUTICAL AND FOOD COMPOSITIONS FOR THE PREVENTION, ALLEVIATION, OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING 1-ALKYL-5-ARYLIDENE-2-SELENOXOIMIDAZOLIDIN-4-ONE AND ITS DERIVATIVES | Non-Final OA | INDUSTRY ACADEMIC COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY |
| 18710002 | FLUCONAZOLE-COX INHIBITOR HYBRIDS: A DUAL-ACTING CLASS OF ANTIFUNGAL AZOLES | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 17641665 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH CLEC16A DYSFUNCTION OR LOSS | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18007843 | Process for the Preparation of Ticagrelor | Non-Final OA | Zaklady Farmaceutyczne Pol-Pharma S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy